New melanoma treatment on PBS
Ipilimumab is indicated for the treatment of patients with advanced unresectable stage III or IV melanoma who have failed or were intolerant to previous therapy.
It was approved by the TGA two years ago and initially rejected by the PBAC.
Clinical trial results showed a 34% reduction in the risk of death and almost double the chance of a patient surviving for one and two years.
“It is the first therapy to show a long-term survival benefit for some patients in a phase III randomised trial in previously treated